Product Description
S64315, a selective small molecule inhibitor of Mcl-1. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33146521/)
Mechanisms of Action: MCL-1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous, Oral, Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Korea, United States, Unknown Location
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Leukemia
Phase 1: Acute Myeloid Leukemia|Lymphoma, Non-Hodgkin|Multiple Myeloma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
jRCT2041210091 |
jRCT2041210091 | P1 |
Active, not recruiting |
Acute Myeloid Leukemia|Multiple Myeloma|Lymphoma, Non-Hodgkin |
2025-03-31 |
|||
2019-004896-38 |
2019-004896-38 | P2 |
Completed |
Leukemia |
2024-06-07 |
20% |
2025-05-06 |
Treatments|Trial Status |